MedPath

Transfusion of Whole Blood in Acute Bleeding

Conditions
Blood Transfusion
Acute Bleeding
Registration Number
NCT06019364
Lead Sponsor
Sofia Ramström
Brief Summary

Blood collected from blood donors is routinely divided into its different components, red blood cells, plasma and platelets. These components are stored under different storage conditions and their maximum storage time before transfusion is different. Platelets are stored at a maximum of 7 days and at a temperature of 22°C to best preserve their function.

Research has been conduction on blood stored and transfused as whole blood (without separation into the various components), particularly in situations of acute trauma. Region Örebro län will therefore start transfusion of whole blood in such situations. The whole blood units will be stored at 4°C for a maximum of 14 days. This means that the platelets will be stored at a lower temperature than standard and for a longer time period. The research on how this will affect platelet function is limited.

This project aims to determine how the patients are affected regarding coagulation, hemolysis, renal function, immunisation, transfusion reactions and the effect of substances released from the blood cells in the whole blood units during the storage period and if there is an impact on mortality.

Detailed Description

Blood collected from blood donors is routinely divided into its different components, red blood cells, plasma and platelets. These components are stored under different storage conditions and their maximum storage time before transfusion is different. Platelets are stored at a maximum of 7 days and at a temperature of 22°C to best preserve their function.

Platelets function is to contribute to the formation of a clot to stop and prevent bleeding. Previous studies has shown that this might be affected if they are stored refrigerated. Exactly how they are affected is not known and when this occurs during the storage period.

Research has been conduction on blood stored and transfused as whole blood (without separation into the various components), particularly in situations of acute trauma. Region Örebro län will therefore start transfusion of whole blood in such situations. The whole blood units will be stored at 4°C for a maximum of 14 days. This means that the platelets will be stored at a lower temperature than standard and for a longer time period. The research on how this will affect platelet function is limited.

Since transfusion of refrigerated whole blood is a new procedure this project aims to determine how the patients are affected regarding coagulation, hemolysis, renal function, immunisation, transfusion reactions and the effect of substances released from the blood cells in the whole blood units during the storage period and if there is an impact on mortality.

Patients requiring transfusion with a whole blood due to an acute situation with bleeding will be enrolled. Blood samples will be taken from the patients for analysis directly before the transfusion and at various time points after the transfusion. Clinical variables of importance to interpret the effect of the whole blood transfusion will be registered as well as basic information such as sex, age, height, weight, blood group and type of injury causing the bleeding, treatment etc.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Patient with acute bleeding
  • Transfused with whole blood at the time of the acute bleeding episode
Exclusion Criteria
  • Patients where vital information lacking needed to interpret data (i.e. blood cell count)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mortality30 day mortality

Death within 30 days following the transfusion of whole blood

Effect of the whole blood transfusion on coagulationAll transfusions occuring within 24 hours post transfusion of the whole blood unit

Requirement for other transfusions

BleedingAll transfusions occuring within 24 hours post transfusion of the whole blood unit

Bleeding following transfusion of the whole blood unit

Secondary Outcome Measures
NameTimeMethod
Platelet countDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 2, Day 5, Day 30

Platelet count at various time points in conjunction to the whole blood transfusion

Red blood cell countDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 2, Day 5, Day 30

Red blood cell count at various time points in conjunction to the whole blood transfusion

APTT, a marker of coagulation capacityDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of APTT at various time points in conjunction to the whole blood transfusion

PT, a marker of coagulation capacityDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of PT at various time points in conjunction to the whole blood transfusion

Anti-thrombin, a marker of coagulation capacityDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of anti-thrombin at various time points in conjunction to the whole blood transfusion

Fibrinogen, a marker of of coagulation capacityDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of fibrinogen at various time points in conjunction to the whole blood transfusion

ElectrolytesDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Electrolytes at various time points in conjunction to the whole blood transfusion

Creatinine, a marker of of renal functionDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of Creatinine at various time points in conjunction to the whole blood transfusion

HemolysisDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 2, Day 5, Day 30

Hemolysis at various time points in conjunction to the whole blood transfusion

GFR, a marker of renal functionDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of GFR at various time points in conjunction to the whole blood transfusion

Urea, a measure of renal functionDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of urea at various time points in conjunction to the whole blood transfusion

sP-selectin, a soluble marker of platelet activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of sP-selectin at various time points in conjunction to the whole blood transfusion

sGPVI, a soluble marker of platelet activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of sGPVI at various time points in conjunction to the whole blood transfusion

PF4, a soluble marker of platelet activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of PF4 at various time points in conjunction to the whole blood transfusion

MMP9, a soluble marker of platelet activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of MMP9 at various time points in conjunction to the whole blood transfusion

sCD40L, a soluble marker of platelet activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of sCD40L at various time points in conjunction to the whole blood transfusion

sGPV, a soluble marker of platelet activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of sGPV at various time points in conjunction to the whole blood transfusion

SCUBE1, a soluble marker of platelet activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of SCUBE1 at various time points in conjunction to the whole blood transfusion

sTNFR2, a marker of inflammation activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of sTNFR2 at various time points in conjunction to the whole blood transfusion

RANTES, a bio modulating substanceDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of RANTES at various time points in conjunction to the whole blood transfusion

IFN-gamma, a bio modulating substanceDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of IFN-gamma at various time points in conjunction to the whole blood transfusion

IL-7, a bio modulating substanceDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of IL-7 at various time points in conjunction to the whole blood transfusion

TSP1, a soluble marker of platelet activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of TSP1 at various time points in conjunction to the whole blood transfusion

CRP, a marker of inflammation activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of CRP at various time points in conjunction to the whole blood transfusion

sTNFR1, a marker of inflammation activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of sTNFR1 at various time points in conjunction to the whole blood transfusion

D-dimer, a marker of coagulation activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of D-dimer at various time points in conjunction to the whole blood transfusion

vWF, a marker of coagulation activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of vWF at various time points in conjunction to the whole blood transfusion

TAT, a marker of coagulation activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of TAT at various time points in conjunction to the whole blood transfusion

VEGF, a bio modulating substanceDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of VEGF at various time points in conjunction to the whole blood transfusion

Serum amyloid A (SAA), a marker of inflammation activationDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of Serum amyloid A at various time points in conjunction to the whole blood transfusion

TNF-alfa, a bio modulating substanceDay 0-pre transfusion, Day 0-post transfusion, Day 1, Day 5 and Day 30

Analysis of TNF-alfa at various time points in conjunction to the whole blood transfusion

ImmunisationWithin 30 days post transfusion

Occurence of immunisation following transfusion of the whole blood

Trial Locations

Locations (1)

Örebro University

🇸🇪

Örebro, Sweden

© Copyright 2025. All Rights Reserved by MedPath